Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

2247 - Comprehensive Genomic Profiling of Primary and Metastatic CDH1 Mutated Classic and Pleomorphic Invasive Lobular Breast Carcinomas Reveals Markers of Hormonal Therapy Resistance and Opportunities for Targeted Therapies

Date

10 Sep 2017

Session

Breast cancer, metastatic

Presenters

Jeffrey Ross

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

J.S. Ross1, L.M. Gay2, J.A. Elvin3, J. Suh3, J. Vergilio3, S. Ramkissoon3, E. Severson3, S. Daniel3, G.M. Frampton3, D. Fabrizio3, A.B. Schrock4, S.M. Ali3, V.A. Miller3, P. Stephens5, J. Chung2

Author affiliations

  • 1 Pathology, Albany Medical Center, 12208 - Albany/US
  • 2 Pathology, Foundation Medicine, 02141 - Cambridge/US
  • 3 R & D, Foundation Medicine, 02141 - Cambridge/US
  • 4 Clinical Development, Foundation Medicine, MA 02141 - Cambridge/US
  • 5 R & D, Foundation Medicine, MA 02141 - Cambridge/US
More

Resources

Abstract 2247

Background

Although invasive lobular breast cancer (ILC) is typically combined with the far more frequent ductal disease for clinical trials and research studies. We queried whether classic (CILC) and its uncommon pleomorphic variant (PILC) featured unique genomic alterations (GA) which could influence therapy for patients with relapsed and refractory disease.

Methods

From a series of 10,784 invasive breast carcinomas DNA was extracted from 40 µm of FFPE sections of 454 (4%) CDH1 mutated ILC including 428 classic (CILC) (94%) and 26 pleomorphic (PILC) (6%) subtypes. CGP was performed on hybridization-captured, adaptor ligation-based libraries (mean coverage depth >600X) for up to 315 cancer-related genes. Total mutational burden (TMB) was determined on 1.2 Mbp of sequenced DNA.

Results

Median age at 63 years was similar for both CILC and PILC (see Table). Clincal ER+ status (p) was higher in CILC and HER2+ status was higher in PILC (P 

Conclusions

Both CILC and PILC show differences in GA in pre-treatment primary vs metastatic lesions in important genes such as ESR1 and ERBB2 likely reflecting the impact of primary therapies. Relapsed CILC is more often driven by ESR1 GA and PILC by ERBB2 GA. Both the CILC and PILC groups have subsets with high TMB, more frequent in PILC, indicating potential for immunotherapies for these patients.

Clinical trial identification

Legal entity responsible for the study

Jeffrey S Ross

Funding

None

Disclosure

J.S. Ross, V.A. Miller, P. Stephens: Employee, leader and owns stock in Foundation Medicine. L.M. Gay, J.A. Elvin, J-A. Vergilio, S. Ramkissoon, E. Severson, S. Daniel, G.M. Frampton, D. Fabrizio, A.B. Schrock, S.M. Ali, J. Chung, J. Suh: Employee and owns stock in Foundation Medicine.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.